For obesity treatment, dose escalation protocols starting at lower doses (e.g., 2 mg) and gradually increasing to maintenance doses (e.g., 4 mg, 8 mg, or 12 mg) have been studied Link below for more detailed information: Product Overview: Retatrutide research peptide, a novel multi-agonist peptide with activity across GLP-1, GIP, and glucagon pathways
(3) L Pickart, J Michelle Vasquez-Soltero, and A Margolina (2014) GHK and DNA: Resetting the Human Genome to Health Biomed Research International, 2014 Sep 11, Volume 2014, Page 151479
To view a copy of this licence, visit About this article Cite this article Zhang, J., Sun, P., Wu, Z
Camilleri M, Lupianez-Merly C (2024) Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and implications in clinical practice